__NUXT_JSONP__("/drugs/Elpamotide", (function(a,b,c){return {data:[{drug:{slug:a,emaEpar:[],fdaDrugLabel:[],id:a,nciThesaurus:{casRegistry:"673478-49-4",chebiId:b,chemicalFormula:b,definition:"A peptide vaccine containing an HLA-A*2402-restricted epitope of vascular endothelial growth factor receptor (VEGFR) 2 with potential immunostimulatory and antineoplastic activities. Upon administration, VEGFR2-169 peptide vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against VEGFR2-expressing tumor cells. VEGFR2, a receptor tyrosine kinase, is overexpressed by a variety of tumor types; overexpression is associated with tumor cell proliferation and tumor angiogenesis. HLA-A*2402 is an MHC class I molecule that presents antigenic peptides to CD8+ T cells; epitope design restricted to epitopes that bind most efficiently to HLA-A*2402 may improve antigenic peptide immunogenicity.",fdaUniiCode:"S68632MB2G",identifier:"C74090",preferredName:a,semanticType:"Pharmacologic Substance",subclassOf:["C1663","C1752"],synonyms:["ELPAMOTIDE",a,"L-Arginyl-L-phenylalanyl-L-valyl-L-prolyl-L-alpha-aspartylglycyl-L-asparaginyl-L-arginyl-L-isoleucine Human Soluble (Vascular Endothelial Growth Factor Receptor) VEGFR2-(169-177)-peptide","VEGFR2-169","VEGFR2-169 Peptide Vaccine"]},dir:"\u002Fdrugs",path:"\u002Fdrugs\u002FElpamotide",extension:".json",createdAt:c,updatedAt:c}}],fetch:{},mutations:void 0}}("Elpamotide","","2021-10-30T13:44:23.863Z")));